Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed

The advent of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has made dramatic progress for the treatment of non-small cell lung cancer (NSCLC). In several series of clinical studies, anti-PD-1/PD-L1 antibodies have generated durable effects, leading to long-term survival with manageable toxicity for patients with advanced NSCLC (1-6). The potential of these agents to generate durable clinical responses has led to their rapid uptake as standard therapy.